by Asa Elmore | Sep 1, 2021 | Events, News, Presentations, Press Releases
Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...
by Asa Elmore | Aug 9, 2021 | News, Press Releases
Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones – Additional follow-up data on STRO-002 from the Phase 1 dose-escalation cohort were presented at ASCO June 2021; enrollment for the...
by Asa Elmore | May 14, 2020 | News, Press Releases
Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares South San Francisco, Calif., May 14, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery,...
by Asa Elmore | May 11, 2020 | News, Press Releases
Sutro Biopharma Announces Pricing of $85.3 Million Public Offering South San Francisco, Calif., May 11, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated...
by Asa Elmore | Apr 27, 2020 | News, Presentations
Dr. Wendel Naumann of The Levine Cancer Institute, Virtual Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 Dr. Wendel Naumann of The Levine Cancer Institute,...
